<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451617</url>
  </required_header>
  <id_info>
    <org_study_id>201600966</org_study_id>
    <nct_id>NCT03451617</nct_id>
  </id_info>
  <brief_title>Alpine vs. Xpedition: Evaluation of Stent Delivery System</brief_title>
  <acronym>AXES</acronym>
  <official_title>Randomized Clinical Evaluation of Alpine® vs. Xpedition® Stent Delivery System of the XIENCE® Everolimus-eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the performance of two stent delivery systems for percutaneous
      coronary intervention with everolimus-eluting stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: The current gold standard for percutaneous coronary intervention (PCI) is the
      second generation drug-eluting stent (DES). The most commonly used DES is the
      everolimus-eluting stent (EES). New stent delivery systems for PCI with EES are developed to
      optimize strength, flexibility and pushability of the catheter. The effect on procedural time
      of new stent delivery systems has not yet been investigated in clinical practice.

      Objective: To evaluate and compare the performance of two stent delivery systems for PCI with
      EES.

      Study design: Randomized comparative trial with 500 patients in the University Medical Center
      Groningen (UMCG).

      Study population: All patients undergoing PCI with EES, aged 18 years or older, will be
      considered for eligibility. Patients will be excluded when scheduled for chronic total
      occlusion (CTO) PCI or if verbal informed consent cannot be obtained.

      Intervention: The first group will undergo PCI with the XIENCE EES using the Alpine stent
      delivery system, the second group will undergo PCI with the Xpedition stent delivery system.

      Main study parameters/endpoints: The primary endpoint is the proportion of procedures with
      crossing time (from introduction of guidewire to stent deployment) longer than 30 minutes.
      Secondary endpoints include procedural time (from heparin administration to removal of
      catheter sheath, mins), use of additional materials, total procedural costs, radiation dose
      (μGym2), radiation time (mins), and contrast dose (ml).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Anticipated">October 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crossing time</measure>
    <time_frame>During PCI procedure</time_frame>
    <description>Proportion of procedures with crossing time (from introduction of guidewire to stent deployment) longer than 30 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural time</measure>
    <time_frame>During PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedural costs</measure>
    <time_frame>During PCI procedure</time_frame>
    <description>Total cost of the materials used during the procedure (stent delivery system and additional materials) in euros.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dose</measure>
    <time_frame>During PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation time</measure>
    <time_frame>During PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast dose</measure>
    <time_frame>During PCI procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Xpedition stent delivery system</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpine stent delivery system</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent delivery with Xpedition</intervention_name>
    <description>Use of Xpedition stent delivery system to implant the XIENCE stent</description>
    <arm_group_label>Xpedition stent delivery system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent delivery with Alpine</intervention_name>
    <description>Use of Alpine stent delivery system to implant the XIENCE stent</description>
    <arm_group_label>Alpine stent delivery system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing PCI with EES, aged 18 years or older

        Exclusion Criteria:

          -  Chronic total occlusion (CTO) PCI

          -  Inability to obtain (verbal) informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pim van der Harst, Prof. Dr.</last_name>
    <phone>+31 50 3612355</phone>
    <email>p.van.der.harst@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pim van der Harst, Prof. Dr.</last_name>
      <email>p.van.der.harst@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Groningen</investigator_affiliation>
    <investigator_full_name>Pim van der Harst</investigator_full_name>
    <investigator_title>Prof. Dr. P. van der Harst</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

